Redeye leaves a comment on the Q4 report published by Alzinova earlier today.
Spotlight Group redovisade en nettoomsättning över förväntan i kv4 2023, vilket är positivt givet at...
Sales36.0m (-3% vs. ABGSCe), adj. EBIT 15.6m (+1% vs.
Group net sales was EUR 28.0m in Q4 (LSEG consensus EUR 27.
Redeye reviews its financial estimates on all time horizons following Episurf Medical's most recent ...
Sales -3% and adj. EBITA -6% vs. ABGSCe Inission outperforms while Enedo underperforms vs.
Strax continues to focus on reducing its debt and restructuring its operation.
Following the publication of BankNordik's 2023 annual report, we make only minor changes to our P&L ...
Redeye place its coverage of TECO 2030 ''Under Review'' as the company currently lacks financing.
Cantargia flaggar för att inleda en proof-of-concept studie som förstahandsval vid metastaserad buks...
TCECUR har publicerat bolagets Q4-rapport.
Pharma Equity Group (“PEG” or “the Company”), through the Company’s subsidiary, Reponex, employs a d...
Trots en svag byggkonjunktur i flera länder förväntas den organiska försäljningen fortsätta att öka,...
Omsättningen i linje med våra helårsestimat Omsättningen i kvartalet uppgick till 48,3 mkr, vilket m...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
Lipigon fick godkännande att inleda fas 2-studie med Lipisense.
Redeye leaves its initial take on Lifecare's year-end report that came in higher than anticipated on...
Q-linea has finished 2023 and also started 2024 with plenty of action.
LumiGruppen is one of the leading private education providers in Norway, a frontrunner in the privat...
Q4 EBITDA of -1.5m vs ABGSCe 0.9m Focus on executing on growth strategy Only small estimate changes ...
